Trial Outcomes & Findings for Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria (NCT NCT00724698)

Results Overview

Number of adverse events reported

Recruitment status

COMPLETED

Target enrollment

3011 participants

Primary outcome timeframe

Final Visit (Day 15)

Results posted on

2022-02-09

Participant milestones
Measure	Desloratadine Desloratadine 5 mg daily
Overall Study STARTED	3011
Overall Study COMPLETED	2921
Overall Study NOT COMPLETED	90

Reasons for withdrawal
Measure	Desloratadine Desloratadine 5 mg daily
Overall Study Adverse Event	9
Overall Study Failure of Therapy	4
Overall Study Poor Compliance	16
Overall Study Lost to Follow-up	36
Overall Study No Info	25

Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria

Baseline characteristics by cohort
Measure	Desloratadine n=3011 Participants Desloratadine 5 mg daily
Age, Categorical <=18 years	239 Participants n=5 Participants
Age, Categorical Between 18 and 65 years	2542 Participants n=5 Participants
Age, Categorical >=65 years	230 Participants n=5 Participants
Sex: Female, Male Female	1788 Participants n=5 Participants
Sex: Female, Male Male	1223 Participants n=5 Participants

Timeframe: Final Visit (Day 15)

Number of adverse events reported

Outcome measures
Measure	Desloratadine n=3011 Participants Desloratadine 5 mg daily
Adverse Events Mild	41 adverse events reported
Adverse Events Moderate	15 adverse events reported
Adverse Events Severe	1 adverse events reported

Adverse event data not reported

Adverse event data not reported

Schering-Plough

Principal investigator is a sponsor employee The PI agree only to use such information to conduct the study and will not be able to publish the results of any part of the study without previous writeen authorization from Schering-Plough.
Publication restrictions are in place

Restriction type: OTHER